Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $110.6 million.

  • Viridian Therapeutics, Inc.\DE's Operating Expenses rose 3233.01% to $110.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $398.9 million, marking a year-over-year increase of 4078.54%. This contributed to the annual value of $299.3 million for FY2024, which is 1749.58% up from last year.
  • Viridian Therapeutics, Inc.\DE's Operating Expenses amounted to $110.6 million in Q3 2025, which was up 3233.01% from $106.8 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Operating Expenses high stood at $110.6 million for Q3 2025, and its period low was $14.3 million during Q3 2021.
  • Moreover, its 5-year median value for Operating Expenses was $56.0 million (2024), whereas its average is $57.1 million.
  • Data for Viridian Therapeutics, Inc.\DE's Operating Expenses shows a peak YoY increase of 19177.62% (in 2021) and a maximum YoY decrease of 6768.41% (in 2021) over the last 5 years.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Operating Expenses (Quarter) stood at $29.3 million in 2021, then soared by 67.85% to $49.2 million in 2022, then soared by 45.51% to $71.6 million in 2023, then rose by 22.35% to $87.5 million in 2024, then rose by 26.32% to $110.6 million in 2025.
  • Its Operating Expenses stands at $110.6 million for Q3 2025, versus $106.8 million for Q2 2025 and $93.9 million for Q1 2025.